RSRaghav Sehgal

Raghav Sehgal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Raghav Sehgal has a total of 137 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    When to Trust Epigenetic Clocks: Avoiding False Positives in Aging Interventions

    by Daniel S. Borrus, Raghav Sehgal, Jenel Fraij Armstrong, Jessica Kasamoto, John Gonzalez, Albert Higgins‐Chen

    Epigenetic clocks have emerged as potential biomarkers of aging due to their association with morbidity and mortality. They have recently gained traction as outcome measurements for anti‐aging interventions. However, as the number of new epigenetic clocks continues to grow, different clocks may not agree on the effect of an intervention. This raises the question of when researchers can trust epigenetic clock results. In this study, we find that when extending previously published single‐clock intervention studies to include additional clock models, no additional clocks reach statistical significance. We then analyze clock behavior across positive control datasets (age‐accelerating events) to propose three criteria that increase confidence in a result: (1) reliable PC‐based clocks respond, (2) mortality‐trained or pace‐of‐aging clocks respond, and (3) multiple clocks respond in the same direction. To explain why genuine effects would appear across multiple clocks, we perform a simulation study to demonstrate how reliable clocks are more sensitive to true effects, and use longitudinal control datasets to show that reliable clock changes are correlated with each other. We then show examples of interventions that do satisfy these criteria. These findings provide a framework for interpreting epigenetic clock results in anti‐aging intervention studies, and suggest that some previously published single‐clock findings may warrant reexamination.

  • Open Access

    Responsiveness of epigenetic aging biomarkers to longevity interventions in humans

    by Raghav Sehgal, Daniel Borrus, Jenel F. Armstrong, John Gonzalez, Jessica Kasamoto, Yaroslav Markov, Ahana Priyanka, Ryan Smith, Natàlia Carreras-Gallo, Jessica Lasky-Su, et al.

    Aging biomarkers can potentially allow researchers to rapidly monitor the impact of an aging intervention without the need for decade-spanning trials. However, before the use of aging biomarkers, such as epigenetic clocks, as surrogate endpoints, their responsiveness to interventions that target aging must be tested. Here we curate TranslAGE, a harmonized database of 51 public and private longitudinal interventional studies, and calculate a consistent set of 16 prominent epigenetic clocks for each study, along with 94 other DNA methylation (DNAm) biomarkers that can help explain the changes observed for each clock. Using this database, we discover patterns of responsiveness across a variety of interventions and DNAm biomarkers. For example, clocks trained to predict mortality or pace of aging show the strongest responses across all interventions and show consistent results with one another; pharmacological and lifestyle interventions drive the strongest responses from DNAm biomarkers; and the characteristics of the study population and study duration are key factors in determining the responsiveness of DNAm biomarkers to an intervention. Moreover, clocks with multiple subscores (that is ‘explainable clocks’) provide specificity and greater mechanistic insight into the responsiveness of interventions than single-score clocks. These findings can help to design future clinical trials by guiding the choice of interventions and of specific subsets of DNAm biomarkers to minimize multiple testing, study duration, study population and sample size, with the eventual aim of uncovering DNAm biomarkers that can be used as surrogate aging endpoints.


  • Open Access

    Biological Versus Technical Reliability of Epigenetic Clocks and Implications for Disease Prognosis and Intervention Response

    by Raghav Sehgal, Daniel S. Borrus, John Gonzalez, Yaroslav Markov, Albert Higgins‐Chen, Alzheimer'S Disease Neuroimaging Initiative

    Epigenetic clocks are widely used to estimate biological age and predict health outcomes, but their translational value depends not only on accuracy but also on reliability. Using the TranslAGE platform, we evaluated both technical and biological reliability across 18 DNA methylation–based aging biomarkers, including chronological, mortality, and pace‐of‐aging clocks. Most clocks demonstrated excellent technical reproducibility across replicate assays on EPIC and 450 K arrays. However, several showed sensitivity to experimental factors such as slide position and DNA extraction protocols. In contrast, PC‐based clocks, particularly PCGrimAge and SystemsAge, remained robust across conditions. Biological reliability, assessed across repeated measures collected within short intervals under varying conditions such as meals, stress, and environmental exposures, was substantially lower. Most clocks showed only low to moderate stability which further decreased when adjusting for immune composition. Notably, technical reproducibility did not predict biological reliability. We further show that reliability directly impacts downstream applications. Clocks with higher reliability produced more stable associations with cognitive outcomes and more consistent responses to interventions, while less reliable clocks yielded variable or misleading results. These findings highlight a critical limitation in current epigenetic clocks. Improving biological reliability will be essential for advancing their use in clinical and interventional settings.


  • Open Access

    CpG Atlas: A centralized multi-layer database and AI interface for DNA methylation research

    by Jenel F. Armstrong, Shawn Wahi, Daniel Borrus, Raghav Sehgal, Syed Rizvi, Shiyang Zhang, Macsue Jacques, Nir Eynon, David van Dijk, Albert Higgins-Chen

    DNA methylation research has vastly expanded over the past decade, producing a wealth of epigenome-wide association studies, biomarker algorithms such as epigenetic clocks, technical performance analyses, and functional annotations for CpG sites. However, these resources remain fragmented across dozens of databases and supplementary files within manuscripts, forcing researchers to spend time and effort on data cleaning and integration prior to meaningful analyses. No single resource currently unifies this information into a centralized, easy-to-query framework. Here, we present CpG Atlas, a curated relational database that integrates 18 distinct annotation layers encompassing over 1.2 million CpG sites across all four generations of Illumina methylation arrays (HM450K, EPIC v1, EPIC v2, and MSA). Built on a snowflake schema with a canonical probe identifier hub implemented in SQL, CpG Atlas consolidates over 800,000 CpG-trait associations, results from Mendelian randomization analyses, CpG membership across 81 epigenetic clocks, array manifest information, and probe reliability data. It further includes specialized layers such as solo-WCGW, CoRSIVs, PRC2 binding, transposon and retroelement annotations, tissue-specific differentially methylated positions across 17 tissues, and hallmarks of aging and cancer. To maximize utility and ease of use, the database is paired with an interactive web tool and a natural language-to-SQL query interface, enabling users to quickly perform complex multi-dimensional queries. Detailed documentation about every data source and table is also provided, facilitating the identification and interpretation of relevant studies. We demonstrate the utility of CpG Atlas through two case studies: a systematic enrichment analysis revealing distinct functional signatures across 16 epigenetic clocks, and an iterative biomarker discovery workflow for IBD that leverages cross-layer integration. Because it is readily scalable simply by adding or updating tables in the database, CpG Atlas provides a continuously evolving and extensible infrastructure for the epigenetics community that supports collaborative research, interpretable biomarker development, and integrative analyses across the growing landscape of epigenetic data.


    • 1 March 2026
      • Vol. 25  (3) , e70430
    Open Access

    DNA Methylation Signatures of Cellular Senescence Are Not Reversed by Senolytic Treatment.

    by Jessica Kasamoto, John González, Yaroslav Markov, Raghav Sehgal, Edwin Lee, Varun B Dwaraka, Ryan Smith, Albert T Higgins-Chen

    Epigenetic clocks are commonly used aging biomarkers based on DNA methylation that predict long-term morbidity and mortality risk. Increased cellular senescence with age is also posited to contribute to age-related disease and mortality. However, prior studies have found that existing epigenetic clocks show inconsistent associations with cellular senescence and no reductions after senolytic treatment. We hypothesize this reflects that senescence-related CpGs are a small proportion of age-related CpGs, and that an epigenetic clock focused on a core senescence signal conserved across different cell types and different senescence inducers would be a better tool for monitoring senescence and senolytic treatment compared to traditional epigenetic clocks. In our study, we find that senescence, age and mortality risk intersect at a small subset of the DNA methylome (9363 CpGs out of 396,333 analyzed; 2.4%). Utilizing these CpGs, we generated three different epigenetic clocks trained to predict in vitro senescence, age, and mortality, respectively. Surprisingly, all three of these predictors stayed the same or even accelerated after senolytic treatment in both in vivo and in vitro data. Our findings not only call into question whether cellular senescence can be captured by DNA methylation but also challenge the assumption that aging biomarkers decrease after geroscience interventions.

  • Open Access

    DNA Methylation Signatures of Cellular Senescence Are Not Reversed by Senolytic Treatment

    by Jessica Kasamoto, John González, Yaroslav Markov, Raghav Sehgal, Edwin Lee, Varun B. Dwaraka, Ryan Smith, Albert T. Higgins‐Chen

    Epigenetic clocks are commonly used aging biomarkers based on DNA methylation that predict long‐term morbidity and mortality risk. Increased cellular senescence with age is also posited to contribute to age‐related disease and mortality. However, prior studies have found that existing epigenetic clocks show inconsistent associations with cellular senescence and no reductions after senolytic treatment. We hypothesize this reflects that senescence‐related CpGs are a small proportion of age‐related CpGs, and that an epigenetic clock focused on a core senescence signal conserved across different cell types and different senescence inducers would be a better tool for monitoring senescence and senolytic treatment compared to traditional epigenetic clocks. In our study, we find that senescence, age and mortality risk intersect at a small subset of the DNA methylome (9363 CpGs out of 396,333 analyzed; 2.4%). Utilizing these CpGs, we generated three different epigenetic clocks trained to predict in vitro senescence, age, and mortality, respectively. Surprisingly, all three of these predictors stayed the same or even accelerated after senolytic treatment in both in vivo and in vitro data. Our findings not only call into question whether cellular senescence can be captured by DNA methylation but also challenge the assumption that aging biomarkers decrease after geroscience interventions.


  • Top Cited Papers
    Open Access

    OMICmAge quantifies biological age by integrating multi-omics with electronic medical records

    by Qingwen Chen, Varun B. Dwaraka, Natàlia Carreras-Gallo, Jenel F. Armstrong, Raghav Sehgal, M. Austin Argentieri, Anne Richmond, Andrea Aparicio, Kevin Mendez, Yulu Chen, et al.

    Biological aging reflects complex cellular and biochemical processes that can be measured across multiple omic layers. Using routine clinical laboratory data from ~31,000 participants in the Mass General Brigham Biobank, we developed EMRAge, a biomarker of mortality risk that can be broadly recapitulated across electronic medical records. Here we show that EMRAge can be modeled using elastic net regression with DNA methylation and multi-omics to generate DNAmEMRAge and OMICmAge, respectively. Both biomarkers are strongly associated with incident and prevalent chronic diseases and mortality, performing comparably or better than current biomarkers across discovery (Massachusetts General Brigham Aging Biobank Cohort, n = 3,451) and validation cohorts (TruDiagnostic, n = 14,213; Generation Scotland, n = 18,672). Importantly, OMICmAge leverages epigenetic biomarker proxies to integrate proteomic, metabolomic and clinical domains while remaining quantifiable from DNA methylation alone. This framework establishes an accessible, scalable measure of biological aging with potential to reveal molecular interconnections that shape healthspan and disease risk.


  • Open Access

    TranslAGE: A Comprehensive Platform for Systematic Validation of Epigenetic Aging Biomarkers

    by Daniel S. Borrus, Raghav Sehgal, Jenel F. Armstrong, John Gonzalez, Grace Zou, Jessica Kasamoto, Yaroslav Markov, Jessica Lasky-Su, Albert Higgins-Chen

    Epigenetic clocks are powerful biomarkers of biological aging, however, their performance varies across studies and contexts. Current limitations include siloed datasets, inconsistent validation methods, and the absence of a standardized framework for systematic comparison. Here, we introduce TranslAGE: a publicly available online resource that addresses this gap by harmonizing 179 human blood DNA methylation datasets and precalculating a suite of 41 epigenetic biomarker scores for each of the >42,000 total samples. Users can explore these data through interactive dashboards that evaluate four fundamental performance domains: Stability, Treatment response, Associations, and Risk, collectively forming the STAR framework. Stability quantifies robustness to multiple types of technical and biological noise. Treatment response measures biomarker sensitivity to aging interventions and environmental exposures. Associations capture cross-sectional relationships with age, demographics, disease, and other phenotypes, and Risk assesses predictive power for future functional decline, morbidity and mortality. The STAR framework unifies these test metrics into a single composite scoring system that enables researchers to identify, benchmark, and validate biomarkers best suited to their scientific or clinical applications. TranslAGE will be continually updated, with rapid scaling by adding datasets, biomarkers, or analyses. By providing harmonized datasets, precomputed biomarker scores, and interactive data tools, TranslAGE establishes the first standardized, reproducible framework for benchmarking epigenetic aging biomarkers across populations, and accelerates the translation toward clinical use.


  • Open Access

    Biological versus Technical Reliability of Epigenetic Clocks and Implications for Disease Prognosis and Intervention Response

    by Raghav Sehgal, Daniel Borrus, John Gonzalez, Yaroslav Markov, Adni, Albert Higgins-Chen

    DNA methylation–based aging biomarkers, or epigenetic clocks, are increasingly used to estimate biological age and predict health outcomes. Their translational utility, however, depends not only on predictive accuracy but also on reliability, the ability to provide consistent results across technical replicates and repeated biological measures. Here, we leveraged the TranslAGE platform to comprehensively evaluate the technical and biological reliability of 18 Epigenetic clocks, including chronological predictors, mortality predictors, pace-of-aging measures, reliable variants, and newer explainable clocks. Technical reliability was quantified across four independent datasets. For standard replicate assays on EPIC and 450K arrays, nearly all clocks achieved excellent technical reproducibility. However, some clocks showed dramatic drops in technical reliability based on differences in slide position and DNA extraction protocol. PC-based clocks, especially PCGrimAge and SystemsAge remained technically reliable in all cases. In contrast, biological reliability, measured across repeated samples collected within hours, before and after meals, under acute stress, across environmental exposures, and over days, was markedly lower, with most clocks showing only moderate stability. PCGrimAge was the only clock with good ICC > 0.75 for biological reliability. Importantly, technical reproducibility did not predict biological reliability; clocks that were technically robust often proved biologically unreliable. We further demonstrated that reliability directly constrains downstream applications. Clocks with higher ICCs produced more stable prognostic associations with cognitive decline and more consistent responsiveness to a vegan diet intervention, whereas unreliable clocks yielded highly variable or spurious effects. Together, these findings reveal that technical reliability is not enough: biological reliability remains a critical limitation for many DNA methylation clocks that constrains their utility, and our work provides a roadmap for prioritizing next-generation clocks most suited for clinical translation.


  • Top Cited Papers

    Systems Age: a single blood methylation test to quantify aging heterogeneity across 11 physiological systems

    by Raghav Sehgal, Yaroslav Markov, Chenxi Qin, Margarita Meer, Courtney Hadley, Aladdin H. Shadyab, Ramon Casanova, JoAnn E. Manson, Parveen Bhatti, Ann Z. Moore, et al.

    Aging occurs at different rates across individuals and physiological systems, but most epigenetic clocks provide a single age estimate, overlooking within-person variation. Here we developed systems-based DNA methylation clocks that measure aging in 11 distinct physiological systems—Heart, Lung, Kidney, Liver, Brain, Immune, Inflammatory, Blood, Musculoskeletal, Hormone and Metabolic—using data from a single blood draw. By integrating supervised and unsupervised machine learning with clinical biomarkers, functional assessments and mortality risk, we derived system-specific scores that outperformed existing global clocks in predicting relevant diseases and aging phenotypes. We also created a composite Systems Age score to capture overall multisystem aging. Clustering individuals based on these scores revealed distinct biological aging subtypes, each associated with unique patterns of health decline and disease risk. This framework enables a more granular and clinically relevant assessment of biological aging and may support personalized approaches to monitor and target system-specific aging processes.